tiprankstipranks
GlaxoSmithKline (DE:GS71)
XETRA:GS71
Germany Market
GS71
GlaxoSmithKline
RESEARCH TOOLSreports

GlaxoSmithKline (GS71) Stock Forecast & Price Target

5 Followers
See the Price Targets and Ratings of:

GS71 Analyst Ratings

Hold
14Ratings
Hold
4 Buy
8 Hold
2 Sell
Based on 14 analysts giving stock ratings to
GlaxoSmithKline
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

GS71 Stock 12 Month Forecast

Average Price Target

€24.39
▼(-0.89% Downside)
Based on 14 Wall Street analysts offering 12 month price targets for GlaxoSmithKline in the last 3 months. The average price target is €24.39 with a high forecast of €30.41 and a low forecast of €19.66. The average price target represents a -0.89% change from the last price of €24.61.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"14":"€14","31":"€31","18.25":"€18.25","22.5":"€22.5","26.75":"€26.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":30.4087701,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€30.41</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24.39218523818182,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€24.39</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19.655859,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€19.66</span>\n  </div></div>","useHTML":true}}],"tickPositions":[14,18.25,22.5,26.75,31],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.25,21.954520776923076,22.659041553846155,23.36356233076923,24.06808310769231,24.772603884615386,25.47712466153846,26.181645438461537,26.886166215384616,27.590686992307695,28.29520776923077,28.999728546153847,29.704249323076922,{"y":30.4087701,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.25,21.491706556783218,21.733413113566435,21.975119670349653,22.216826227132866,22.458532783916084,22.7002393406993,22.94194589748252,23.183652454265737,23.425359011048954,23.667065567832168,23.908772124615385,24.150478681398603,{"y":24.39218523818182,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.25,21.12737376923077,21.004747538461537,20.88212130769231,20.759495076923077,20.636868846153845,20.514242615384614,20.391616384615386,20.268990153846154,20.146363923076922,20.02373769230769,19.901111461538463,19.77848523076923,{"y":19.655859,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":17.383,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":15.952,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":15.528,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":16.39,"date":1756684800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":18.841,"date":1759276800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":19.801,"date":1761955200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":20.193,"date":1764547200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":20.684,"date":1767225600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":21.864,"date":1769904000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 16</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":24.704,"date":1772323200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 20</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":23.941,"date":1775001600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 21</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":22.138,"date":1777593600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 18</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":21.25,"date":1780272000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 14</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€30.41Average Price Target€24.39Lowest Price Target€19.66
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on DE:GS71
James Gordon CFA
Barclays
Barclays
€20.81
Sell
-15.43%
Downside
Reiterated
06/17/26
GlaxoSmithKline (GSK) Gets a Sell from Barclays
UBS Analyst forecast on DE:GS71
Matthew Weston
UBS
UBS
€22.43
Hold
-8.85%
Downside
Reiterated
06/15/26
UBS Keeps Their Hold Rating on GlaxoSmithKline (GSK)
Intron Health Analyst forecast on DE:GS71
Unknown Analyst
Intron Health
Not Ranked
Intron Health
€23.12
Hold
-6.04%
Downside
Upgraded
06/10/26
GlaxoSmithKline (GSK) was upgraded to a Hold Rating at Intron Health
Bernstein Analyst forecast on DE:GS71
Justin Smith
Bernstein
Bernstein
€30.41
Buy
23.56%
Upside
Assigned
06/09/26
Bernstein Gives a Buy Rating to GlaxoSmithKline (GSK)
Bank of America Securities Analyst forecast on DE:GS71
Sachin Jain
Bank of America Securities
Bank of America Securities
€27.17
Hold
10.41%
Upside
Reiterated
06/09/26
GSK’s Nuvalent Deal Seen as Strategically Attractive but Balanced by Execution and EPS Risks; Hold Rating and 2,350 GBp Price Target Maintained
Goldman Sachs Analyst forecast on DE:GS71
Rajan Sharma
Goldman Sachs
Goldman Sachs
€21.62
Hold
-12.14%
Downside
Reiterated
06/09/26
GSK’s Nuvalent Deal Strengthens Oncology Pipeline but Near‑Term EPS Dilution and Fully Valued Shares Justify Hold Rating
J.P. Morgan Analyst forecast on DE:GS71
Zain Ebrahim
J.P. Morgan
J.P. Morgan
€19.66
Sell
-20.13%
Downside
Reiterated
06/09/26
J.P. Morgan Keeps Their Sell Rating on GlaxoSmithKline (GSK)
Deutsche Bank Analyst forecast on DE:GS71
Emmanuel Papadakis
Deutsche Bank
Deutsche Bank
€21.97
Hold
-10.73%
Downside
Reiterated
06/08/26
Deutsche Bank Reaffirms Their Hold Rating on GlaxoSmithKline (GSK)
Jefferies Analyst forecast on DE:GS71
Michael Leuchten
Jefferies
Jefferies
€28.91
Buy
17.45%
Upside
Reiterated
06/03/26
GlaxoSmithKline (GSK) Gets a Buy from Jefferies
Citi Analyst forecast on DE:GS71
Graham Parry
Citi
Citi
―
Hold
―
Reiterated
05/29/26
Analysts Conflicted on These Healthcare Names: GlaxoSmithKline (LSE: GB:GSK) and C4 Therapeutics (NASDAQ: CCCC)
Kepler Capital Analyst forecast on DE:GS71
Nicolas Pauillac
Kepler Capital
Kepler Capital
€29.09
Buy
18.21%
Upside
Upgraded
05/26/26
Positive Report for GlaxoSmithKline (GSK) from Kepler Capital
Berenberg Bank Analyst forecast on DE:GS71
Kerry Holford
Berenberg Bank
Berenberg Bank
€23.12
Hold
-6.04%
Downside
Reiterated
05/05/26
GlaxoSmithKline (GSK) Receives a Hold from Berenberg Bank
DZ BANK AG Analyst forecast on DE:GS71
Elmar Kraus
DZ BANK AG
DZ BANK AG
―
Hold
―
Reiterated
04/29/26
GlaxoSmithKline (GSK) Gets a Hold from DZ BANK AG
Shore Capital Analyst forecast on DE:GS71
Unknown Analyst
Shore Capital
Not Ranked
Shore Capital
―
Buy
―
Reiterated
03/25/26
GlaxoSmithKline (GSK) Gets a Buy from Shore Capital
Morgan Stanley Analyst forecast on DE:GS71
Sarita Kapila
Morgan Stanley
Morgan Stanley
€18.5→€19.66
Sell
-20.13%
Downside
Reiterated
03/02/26
GSK price target raised to 1,700 GBp from 1,600 GBp at Morgan StanleyGSK price target raised to 1,700 GBp from 1,600 GBp at Morgan Stanley
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on DE:GS71
James Gordon CFA
Barclays
Barclays
€20.81
Sell
-15.43%
Downside
Reiterated
06/17/26
GlaxoSmithKline (GSK) Gets a Sell from Barclays
UBS Analyst forecast on DE:GS71
Matthew Weston
UBS
UBS
€22.43
Hold
-8.85%
Downside
Reiterated
06/15/26
UBS Keeps Their Hold Rating on GlaxoSmithKline (GSK)
Intron Health Analyst forecast on DE:GS71
Unknown Analyst
Intron Health
Not Ranked
Intron Health
€23.12
Hold
-6.04%
Downside
Upgraded
06/10/26
GlaxoSmithKline (GSK) was upgraded to a Hold Rating at Intron Health
Bernstein Analyst forecast on DE:GS71
Justin Smith
Bernstein
Bernstein
€30.41
Buy
23.56%
Upside
Assigned
06/09/26
Bernstein Gives a Buy Rating to GlaxoSmithKline (GSK)
Bank of America Securities Analyst forecast on DE:GS71
Sachin Jain
Bank of America Securities
Bank of America Securities
€27.17
Hold
10.41%
Upside
Reiterated
06/09/26
GSK’s Nuvalent Deal Seen as Strategically Attractive but Balanced by Execution and EPS Risks; Hold Rating and 2,350 GBp Price Target Maintained
Goldman Sachs Analyst forecast on DE:GS71
Rajan Sharma
Goldman Sachs
Goldman Sachs
€21.62
Hold
-12.14%
Downside
Reiterated
06/09/26
GSK’s Nuvalent Deal Strengthens Oncology Pipeline but Near‑Term EPS Dilution and Fully Valued Shares Justify Hold Rating
J.P. Morgan Analyst forecast on DE:GS71
Zain Ebrahim
J.P. Morgan
J.P. Morgan
€19.66
Sell
-20.13%
Downside
Reiterated
06/09/26
J.P. Morgan Keeps Their Sell Rating on GlaxoSmithKline (GSK)
Deutsche Bank Analyst forecast on DE:GS71
Emmanuel Papadakis
Deutsche Bank
Deutsche Bank
€21.97
Hold
-10.73%
Downside
Reiterated
06/08/26
Deutsche Bank Reaffirms Their Hold Rating on GlaxoSmithKline (GSK)
Jefferies Analyst forecast on DE:GS71
Michael Leuchten
Jefferies
Jefferies
€28.91
Buy
17.45%
Upside
Reiterated
06/03/26
GlaxoSmithKline (GSK) Gets a Buy from Jefferies
Citi Analyst forecast on DE:GS71
Graham Parry
Citi
Citi
―
Hold
―
Reiterated
05/29/26
Analysts Conflicted on These Healthcare Names: GlaxoSmithKline (LSE: GB:GSK) and C4 Therapeutics (NASDAQ: CCCC)
Kepler Capital Analyst forecast on DE:GS71
Nicolas Pauillac
Kepler Capital
Kepler Capital
€29.09
Buy
18.21%
Upside
Upgraded
05/26/26
Positive Report for GlaxoSmithKline (GSK) from Kepler Capital
Berenberg Bank Analyst forecast on DE:GS71
Kerry Holford
Berenberg Bank
Berenberg Bank
€23.12
Hold
-6.04%
Downside
Reiterated
05/05/26
GlaxoSmithKline (GSK) Receives a Hold from Berenberg Bank
DZ BANK AG Analyst forecast on DE:GS71
Elmar Kraus
DZ BANK AG
DZ BANK AG
―
Hold
―
Reiterated
04/29/26
GlaxoSmithKline (GSK) Gets a Hold from DZ BANK AG
Shore Capital Analyst forecast on DE:GS71
Unknown Analyst
Shore Capital
Not Ranked
Shore Capital
―
Buy
―
Reiterated
03/25/26
GlaxoSmithKline (GSK) Gets a Buy from Shore Capital
Morgan Stanley Analyst forecast on DE:GS71
Sarita Kapila
Morgan Stanley
Morgan Stanley
€18.5→€19.66
Sell
-20.13%
Downside
Reiterated
03/02/26
GSK price target raised to 1,700 GBp from 1,600 GBp at Morgan StanleyGSK price target raised to 1,700 GBp from 1,600 GBp at Morgan Stanley
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering GlaxoSmithKline

3 Months
Justin SmithBernstein
Success Rate
12/20 ratings generated profit
60%
Average Return
+2.48%
Copying Justin Smith's trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +2.48% per trade.
1 Year
Michael LeuchtenJefferies
Success Rate
20/29 ratings generated profit
69%
Average Return
+5.74%
Copying Michael Leuchten's trades and holding each position for 1 Year would result in 68.97% of your transactions generating a profit, with an average return of +5.74% per trade.
2 Years
Justin SmithBernstein
Success Rate
15/20 ratings generated profit
75%
Average Return
+12.46%
Copying Justin Smith's trades and holding each position for 2 Years would result in 75.00% of your transactions generating a profit, with an average return of +12.46% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

GS71 Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
0
0
0
0
0
Buy
8
10
10
7
7
Hold
22
21
21
19
23
Sell
16
20
21
18
14
Strong Sell
0
0
0
0
0
total
46
51
52
44
44
In the current month, GS71 has received 7 Buy Ratings, 23 Hold Ratings, and 14 Sell Ratings. GS71 average Analyst price target in the past 3 months is 24.39.
Each month's total comprises the sum of three months' worth of ratings.

GS71 Financial Forecast

GS71 Earnings Forecast

Next quarter’s earnings estimate for GS71 is €0.52 with a range of €0.46 to €0.54. The previous quarter’s EPS was €0.54. GS71 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year GS71 has Performed in-line its overall industry.
Next quarter’s earnings estimate for GS71 is €0.52 with a range of €0.46 to €0.54. The previous quarter’s EPS was €0.54. GS71 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year GS71 has Performed in-line its overall industry.

GS71 Sales Forecast

Next quarter’s sales forecast for GS71 is €9.47B with a range of €9.40B to €9.62B. The previous quarter’s sales results were €8.80B. GS71 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year GS71 has Performed in-line its overall industry.
Next quarter’s sales forecast for GS71 is €9.47B with a range of €9.40B to €9.62B. The previous quarter’s sales results were €8.80B. GS71 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year GS71 has Performed in-line its overall industry.

GS71 Stock Forecast FAQ

What is DE:GS71’s average 12-month price target, according to analysts?
Based on analyst ratings, GlaxoSmithKline’s 12-month average price target is 24.39.
    What is DE:GS71’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for DE:GS71, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is GlaxoSmithKline a Buy, Sell or Hold?
        GlaxoSmithKline has a consensus rating of Hold, which is based on 4 buy ratings, 8 hold ratings and 2 sell ratings.
          What is GlaxoSmithKline’s share price target?
          The average share price target for GlaxoSmithKline is 24.39. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is €30.41 ,and the lowest forecast is €19.66. The average share price target represents -0.89% Decrease from the current price of €24.61.
            What do analysts say about GlaxoSmithKline?
            GlaxoSmithKline’s analyst rating consensus is a Hold. This is based on the ratings of 14 Wall Streets Analysts.
              How can I buy shares of GlaxoSmithKline?
              To buy shares of DE:GS71, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.